Navigation Links
Paresthesia in Medical News

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), ... 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia ...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

... investigators as possibly related to Contrave treatment. These include cholecystitis (gallbladder inflammation) (2), seizure (2), palpitations (1), paresthesia (1) and vertigo (1). The most frequently observed treatment-emergent adverse events were nausea, constipation and headache. Nausea was the leading ...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

... (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness ...

Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease

... the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling) and pruritus (itching). About CSL Behring CSL Behring is the maker of Alpha1-Proteinase Inhibitor (Human), Zemaira. The company is a ...

Attention: Extra-hepatic manifestation of hepatitis C virus infection

... 76.5% of the patients had extra-hepatic manifestations. Common manifestations were fatigue (59.6%), renal impairment (25%), type 2 diabetes (22.8%), paresthesia (19.9%), arthralgia (18.4%), and purpura predominantly of the lower limbs (17.6%). Over 37% of the patients had cryoglobulins, and 8.8% had B-cell ...

FDA Approves New Product to Treat Von Willebrand Disease

... clinical studies, 15.8 percent of subjects and 5.7 percent of infusions were accompanied by adverse reactions, most commonly itching, pharyngitis, paresthesia (a sensation of numbness and tingling on the skin) and headache, swelling of the face, and rash and chills. Source-Bio-Bio ...
Paresthesia in Medical Technology

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia ... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), ... 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia ...

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

... malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs. ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), ...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

... (13 percent, 5 percent) , Abdominal Pain (11 percent, 0 percent), Shoulder Pain (8 percent, 0 percent), Dyspepsia (7 percent, 0 percent), and paresthesia (6 percent, 0 percent). -- As with all therapeutic proteins, patients may develop antibodies to the therapeutic protein. About Amgen ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs. ...

Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease

... following treatment-related adverse reactions were reported in 1 percent of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling) and pruritus (itching). Zemaira is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious ...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

... persistent neuropathy occurred in 48% (all grades) and 6% (grade 3/4) of patients. In patients with stage II and III colon cancer, paresthesia was seen in 92% (all grades) and 13% (grade 3/4) of patients; 21% (all grades), 0.5% (grade 3/4) had residual paresthesia at 18-month ...
Paresthesia in Medical Products

Precision SCS System

Description:... PRECISION represents a major advance in neurostimulation. With PRECISION, paresthesia can be tightly focused to cover pain. This is done by smoothly moving stimulation where you need it, anywhere along the lead or between ...
Company:Advanced Bionics Corporation
Paresthesia in Medical Dictionary

Paresthesia

... paresthesia : Abnormal sensations such as burning, tingling, or a "pins-and-needles" feeling. paresthesia may constitute the first group of symptoms of ... side effect that does not worsen with time. paresthesia s ( Numbness and Tingling ) Paroxysm al ...

Peripheral neuropathy

... pains and wind , which is reversible when intake is reduced.9 ... paresthesia may constitute the first group of symptoms of peripheral neuropathy , ... a limited drug side effect that does not worsen with time. Circumoral paresthesia affects the area around the mouth. Tacticon Noninvasive hand -held ...

Stimulus

... a small hammer , the lower leg kicks forward strongly. CIRCUMORAL paresthesia : An abnormal touch sensation, such as burning or prickling around the mouth, often in the absence of an external stimulus . See paresthesia . They also help practitioners gauge physical feedback to a stimulus ...

Anterior

... removed half my colon and most of my rectum , and joined up the remaining colon to what's left of my rectum . general; Pare's suture ; paresthesia ; paresthetic; parethmoid; paretic; paretic impotence ; paretic neurosyphilis ; pareunia; parfocal objectives; pargasite; pargyline; pargyline ...

Heat intolerance

... skin , and heat intolerance . Mucous membrane involvement may result in a foul- smell ing nasal discharge . Numbness Abnormal sensations ( paresthesia ); "pins and needles" Painful sensations Muscle weakness Muscle cramps or muscle aches Heat intolerance , especially after exercise ...

Impotence

... ; parent material; parents; parepicele; par epididymis ; parepithymia; parerethisis; parergasia; paresis ; paresis , general; Pare's suture ; paresthesia ; paresthetic; parethmoid; paretic; paretic impotence ; ... Impotence (Erectile Dysfunction) Im pulse -Control Disorders Inborn Errors of ...

Muscle aches

... , vomiting , and diarrhea . Patients also may bleed or bruise easily, get a skin rash , or have swelling . Numbness Abnormal sensations ( paresthesia ); "pins and needles" Painful sensations Muscle weakness Muscle cramps or muscle aches Heat intolerance , especially after exercise ...

Muscle cramps

... fluid (and electrolyte) balance, and causes nausea , vomiting , muscle cramps , confusion and convulsions . Numbness Abnormal sensations ( paresthesia ); "pins and needles" Painful sensations Muscle weakness Muscle cramps or muscle aches Heat intolerance , especially after exercise ...

Neuralgia

... post -herpetic neuralgia . People with intra ctable post -herpetic pain often become depressed. Acute and postherpetic neuralgia Painful paresthesia and dysesthesia. Thoracic and cranial nerve V are most common. This is a condition called postherpetic neuralgia . It is most likely to ...

Neurosyphilis

... ; parent material; parents; parepicele; par epididymis ; parepithymia; parerethisis; parergasia; paresis ; paresis , general; Pare's suture ; paresthesia ; paresthetic; parethmoid; paretic; paretic impotence ; paretic neurosyphilis ; ... 2 A form of neurosyphilis ( syphilis affecting the ...

More>>

Paresthesia in Biological Technology

New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation

... 3/4) of patients. In patients with stage II and III colon cancer, paresthesia was seen in 92% (all grades) and 13% (grade 3/4) of patients; 21% (all grades), 0.5% (grade 3/4) had residual paresthesia at 18-month follow-up -- Hepatotoxicity, as evidenced in the adjuvant ...
Other Contents
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Horizon Blue ... the 50 Best Companies for Latinas in the LATINA Style 50 Report that recognizes ... , For 2015, Horizon BCBSNJ climbs from number 24 to 21 ...
(Date:9/1/2015)... Jose, CA (PRWEB) , ... September 01, 2015 ... ... cross-device computing and collaboration, announces Splashtop Business for Remote Support , a ... remote support solution. Unhappy with the escalating renewal prices and inadequate customer ...
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... Professional Background Screeners (NAPBS®) has announced that Edge Information Management has ... by the Background Screening Credentialing Council (BSCC). , “Achieving and maintaining ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit ... version 5.2 of the FirstSpirit Content Management System with new capabilities and enhancements ... version of FirstSpirit, companies will be well on their way to achieving digital ...
(Date:9/1/2015)... ... , ... Two of Washington D.C.’s most respected chefs are using their global ... Recently named “the next big thing” in the culinary world by Elle Spain, award-winning ... behind food and reclaiming culinary traditions on the brink of extinction. According to Amy ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
Other TagsOther Tags